UPDATE: JP Morgan Initiates DaVita HealthCare Partners at Overweight on Growth Outlook
JP Morgan initiated coverage on DaVita HealthCare Partners (NYSE: DVA) with an Overweight rating and a $125 price target.
JP Morgan said, "By combining the steady growth and cash generation of the company's core dialysis business with the best physician practice management asset in the country, HealthCare Partners (HCP), CEO Kent Thiry has positioned DVA at the forefront of a potentially long-term shift in healthcare delivery and reimbursement heading into reform implementation. The capability of properly incentivized, sophisticated primary care physicians to lower system costs is unquestioned, leaving only the pace and magnitude of opportunity to be decided going forward, with DVA perhaps best positioned of all to benefit."
DaVita HealthCare Partners closed at $110.87 on Wednesday.
Latest Ratings for DVA
|Sep 2016||Raymond James||Upgrades||Market Perform||Outperform|
|Sep 2016||Bank of America||Downgrades||Buy||Neutral|
|Sep 2016||Citigroup||Initiates Coverage on||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.